Beyond Air Inc. (XAIR) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While XAIR currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.04) and Max Pain ($2.43) forces dealer call-delta covering toward $55.86.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Beyond Air Inc. (XAIR) dropped -2.12% to $2.31, trading at 2% of its 52-week range ($2.05 – $53.2). Stretched risk/reward at 112x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.
GARDEN CITY, N.Y., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nit
Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG) stock increased
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +107.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XAIR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XAIR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Beyond Air Inc. (XAIR) ranks #599 by composite RQD confidence (42/100, grade D-) and #965 by equity capitalization ($3.8M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while XAIR leads on capital efficiency and profitability with -35.0% ROIC and 3.3% gross margin. NVNO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with XAIR at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XAIR
ACTIVE
Beyond Air Inc. | D- | 42/100 | 112.1x | 3.3% | -35.0% | -2.12% | $3.8M | Benchmark Subject |
| AMIX Autonomix Medical Inc. | D- | 37/100 | — | — | -35.0% | -5.12% | $4.0M | /amix-vs-xair → |
| CODX Co-Diagnostics Inc. | D- | 37/100 | — | 64.3% | -35.0% | -10.49% | $3.5M | /codx-vs-xair → |
| ICCM IceCure Medical Ltd. | D | 46/100 | — | 36.3% | -35.0% | -2.13% | $3.3M | /iccm-vs-xair → |
| NVNO enVVeno Medical Corporation | D | 50/100 | — | — | -35.0% | +4.08% | $4.9M | /nvno-vs-xair → |
In its most recent audited fiscal period (FY2025, filed 2026-03-31), Beyond Air Inc. (XAIR) reported GAAP revenue of $7.7M (+107.3% vs. FY2024 revenue of $3.7M , and +562.6% cumulative change since FY2023) , GAAP net income of $34.3K, operating cash flow of -$18.1M, and free cash flow of -$19.2M (+56.5% YoY). On the balance sheet, XAIR closed FY2025 with $36.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $7.7M | $34.3K | -$18.1M | -$19.2M | $36.8M | — |
| FY2024 (FY) | 2025-03-31 | $3.7M | $48.5K | -$38.2M | -$44.1M | $34.1M | — |
| FY2023 (FY) | 2024-03-31 | $1.2M | $64.3K | -$56.0M | -$56.0M | — | — |
As of 2026-11-01, Beyond Air Inc. (NASDAQ: XAIR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.31 (-2.12% 1D, market cap $3.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XAIR ranks #599 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), XAIR carries a Roarable D- (42/100 RQD), trailing P/E of 112.1x, gross margin of 3.3%, and ROIC of -35.0%. By comparison, AMIX (Autonomix Medical Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and CODX (Co-Diagnostics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while XAIR leads on capital efficiency (-35.0% ROIC).
Per XAIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001641631), Beyond Air Inc. generated $7.7M in revenue (+107.3% YoY), $34.3K in net income, and -$19.2M in free cash flow against $36.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XAIR last traded at $2.31 (-2.12% on volume of 16,530 shares), positioning the stock -24.01% below its 50-day simple moving average ($3.04) and -77.94% below its 200-day simple moving average ($10.47). Across its 52-week range of $2.05 to $53.20, XAIR sits at the 0.5% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.02 to $2.60).
Why XAIR Stock dropped -2.12% Today — RQD Quant Desk Flash. Stretched risk/reward at 112x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.